B.C. Plans World’s First E-Cigarette Public Health Accountability Law Aimed at “Deceptive Marketing”

Oct.10.2025
B.C. Plans World’s First E-Cigarette Public Health Accountability Law Aimed at “Deceptive Marketing”
British Columbia, Canada is advancing what it calls the world’s first e-cigarette Public Health Accountability law, granting the government authority to sue companies for “deceptive marketing.” The move puts public-health risks at the center of vaping industry compliance.

Key Takeaways
 

· First-of-its-kind legislation: British Columbia, Canada is proposing the world’s first public-health accountability bill for e-cigarettes, bringing public-health risks squarely into the regulatory framework.

 

· Focus on “deceptive marketing”: Targets practices such as hiding ingredients and downplaying addictiveness, with a particular emphasis on youth-oriented marketing.

 

· Modeled on tobacco & opioid litigation: Enables the government to initiate or join class actions to recover public-health costs.

Potential North American ripple effects: If passed, it could become a template for vaping oversight and raise compliance thresholds across the industry.

 


2Firsts, October 10, 2025 — According to Canadian media reports, the Government of British Columbia (B.C.) is advancing a new bill designed to make it easier for the province to sue e-cigarette companies over “misleading or deceptive” marketing.

 

At an October 9 press conference, Attorney General Niki Sharma said the vaping sector “targets young people in specific ways,” including failing to fully disclose product ingredients and the risks of nicotine addiction. “This bill will give the government more direct legal tools to address potential harms in the public-health realm,” she said.

 

 

Modeled on Tobacco and Opioid Suits

 

 

Sharma noted the bill mirrors laws that previously allowed governments to seek recovery of public-health costs from tobacco and opioid manufacturers. “We want a framework that lets the government launch similar class actions—or join related cases in other jurisdictions.”

 

If adopted, it would be the first law explicitly holding the vaping industry to account for public-health impacts. It would not automatically penalize companies; the government would still need to bring suit.

 

 

Forthcoming Legislative Agenda

 

 

B.C. also plans to introduce another bill in the spring session addressing environmental and health liabilities for manufacturers of PFAS (“forever chemicals”).

 

Sharma highlighted mounting health controversies among certain occupational groups—particularly firefighters—and noted multiple lawsuits are underway.

 

 

Damages Benchmarks & Industry Fallout

 

 

It remains unclear whether vaping companies could absorb large judgments. As a party to past tobacco litigation, B.C. is set to receive C$3.6 billion over 18 years from a settlement totaling C$32.5 billion. Opioid-related cases are ongoing.

 

Rob Cunningham of the Canadian Cancer Society pointed out that several U.S. cases involving Juul have settled, and a proposed class action is before the Supreme Court of British Columbia. He warned that “vaping is becoming a primary gateway to nicotine dependence among youth,” while long-term health effects remain uncertain.

 

“Evidence on the harms of smoking took decades to establish; research on vaping could take at least 25 years,” Cunningham said. “But if this bill passes, it may change corporate marketing behavior in the meantime.”

 

 

Policy Extensions & Regulatory Trends

 

 

Beyond legislation, B.C. is expanding youth vaping-prevention education. Some public-health groups are urging the province to raise the legal purchase age for vaping products to 21 and to ban flavored products.

 

The bill’s progress could become a landmark in North American regulation of vaping marketing and public-health accountability, with knock-on effects for global compliance standards in novel nicotine products.

 

 

Cover image caption: B.C. Attorney General Niki Sharma, photographed Wednesday, October 8, 2025. Source: Flickr / Government of British Columbia.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
Altria Showcases Ploom, Marlboro Heated Tobacco Sticks and Non-Nicotine Energy Products at NACS Show 2026
Altria Showcases Ploom, Marlboro Heated Tobacco Sticks and Non-Nicotine Energy Products at NACS Show 2026
At the 2026 NACS Show, Altria displayed Ploom devices alongside imagery of Marlboro-branded heated tobacco sticks, while also featuring RIOT Energy and Proper Wild non-nicotine products. The booth showcased on! PLUS nicotine pouches, including 12 mg variants not listed among FDA-authorized products as of October 9, and NJOY e-cigarettes. Altria also presented convenience-store traffic figures highlighting its retail presence. 2Firsts examines the company's expanded product portfolio, non-nicotine business activities and the regulatory status of products displayed at the show.
EXPO
Oct.10
New York City Opens Lottery for 55 Vape Retail License Slots Across 23 Community Districts, Including 28 in Brooklyn
New York City Opens Lottery for 55 Vape Retail License Slots Across 23 Community Districts, Including 28 in Brooklyn
New York City's Department of Consumer and Worker Protection (DCWP) opened applications on November 2, 2026, for a lottery covering tobacco and electronic cigarette retail dealer licenses, with a deadline of 5 p.m. New York local time on November 30. According to the city's October 1 notice, 55 electronic cigarette retail license slots are available across 23 community districts, including 28 in Brooklyn, alongside 322 tobacco retail license slots across 41 districts. Businesses must enter the lottery and, if invited, complete licensing requirements within 65 days. New York City continues to restrict e-cigarette retail sales to tobacco-flavored or unflavored products, while city retail licenses do not replace FDA product marketing authorization.
Market
Nov.04
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24